CHILDREN WITH CYSTIC FIBROSIS HOSPITALISED WITH <scp>COVID</scp>‐19: MULTICENTRE EXPERIENCE

Yazidi, Laila S Al; Maskari, Nawal Al; Reesi, Mohammed Al

doi:10.1111/jpc.15495

Cited by 4 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, decreased TMPRSS2 would reduce SARS-CoV-2 entry into airway epithelial cells. 26,27 In the current study, no cases were admitted to ICU or died because of COVID-19. This could have been due to lower ACE expression in these children and the fact that children with a chronic lung disease such as CF and their parents are more careful about hygiene because of concerns about serious disease, and these precautions were significantly increased during the COVID-19 pandemic.…”

Section: Discussionmentioning

confidence: 80%

An Evaluation of the Risk Factors and Respiratory Function Test Change of Children with Cystic Fibrosis Who Contracted COVID-19 Infection

Özaslan

Şenol

Barlık

et al. 2023

J Pediatr Infect Dis

View full text Add to dashboard Cite

Objective Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a global pandemic in March 2020, with millions of infected cases worldwide. Although the course is usually mild in the pediatric age group, there are unknown factors in patients with chronic lung diseases. The aim of this study was to determine the demographic characteristics and the clinical course of patients with cystic fibrosis who contracted COVID-19 infection. Methods A total of 128 patients with cystic fibrosis who were under follow-up in our clinic were separated into two groups: those who had been infected with COVID-19 and those who had not. The COVID-19-positive patients were then grouped as those who were hospitalized and those treated as outpatients. In the COVID-19 group, the spirometry values of the patients before the infection were compared with those measured at 3 and 6 months after the infection. Results The COVID-19 group comprised 34 (25.6%) cystic fibrosis patients with a mean age of 108.2 ± 60.8 months who contracted COVID-19 between April 2020 and October 2022. The rates of chronic bacterial colonization and allergic bronchopulmonary aspergillosis were significantly higher in the COVID-19 group (p = 0.001 and 0.005). Eight of the 34 patients were hospitalized, and 26 were isolated at home. Five patients required oxygen, and the forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) values were lower. Conclusion A severe course of COVID-19 was not seen in any of the cystic fibrosis patients. A greater number of patients with chronic respiratory tract bacterial colonization and allergic bronchopulmonary aspergillosis were hospitalized.

show abstract

Section: Discussionmentioning

confidence: 80%

An Evaluation of the Risk Factors and Respiratory Function Test Change of Children with Cystic Fibrosis Who Contracted COVID-19 Infection

Özaslan

Şenol

Barlık

et al. 2023

J Pediatr Infect Dis

View full text Add to dashboard Cite

show abstract

“…A total of 31 papers published as observational studies reported an association of COVID-19 in patients with CF [ 18 , 19 , 20 , 21 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ] ( Table 1 ). These studies comprised 661,386 patients in total, including children, adults, and elderly age groups.…”

Section: Resultsmentioning

confidence: 99%

“…However, only 19,150 (2.9%) patients were diagnosed with CF and, from these patients, 2523 (0.4%) were diagnosed with both CF and COVID-19. Regarding patients with CF and COVID-19, the sex proportion was (female/male) 1207/1167 [ 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 41 , 42 , 43 , 45 , 47 , 48 , 49 , 50 ]. Some publications [ 21 , 26 , 35 , 40 , 46 ] did not report the sex of the patients.…”

Section: Resultsmentioning

confidence: 99%

“…Several other pathogens commonly colonize individuals with CF; in fact, several bacteria such as S. aureus, Haemophilus influenzae, P. aeruginosa, and Burkholderia complex have been widely identified in individuals with CF, being that the most common respiratory pathogen in adults is P. aeruginosa, whereas, in children, it is the S. aureus [61,62]. Although individuals with COVID-19 tend to have a relatively low rate of co-infection with bacterial agents, S. pyogenes and S. pneumoniae being the most common microorganisms [63,64], it might not be true for patients with CF and COVID-19, since nearly 25.0% of the patients included in the systematic review presented co-infection of P. aeruginosa and SARS-CoV-2 [19][20][21]24,28,31,33,38,41,44,45,47], which might impair their prognosis. Unfortunately, in our data, we did not have access to bacterial testing data because the Brazilian Ministry of Health did not compute the data into the dataset.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiological Profile of Hospitalized Patients with Cystic Fibrosis in Brazil Due to Severe Acute Respiratory Infection during the COVID-19 Pandemic and a Systematic Review of Worldwide COVID-19 in Those with Cystic Fibrosis

Marques,

Boschiero,

Sansone

et al. 2023

Healthcare

View full text Add to dashboard Cite

Since the onset of the coronavirus disease, COVID-19 pandemic, concern arose for those who might be at higher risk of a worse COVID-19 prognosis, such as those with cystic fibrosis (CF). In this context, we evaluated the features of hospitalized patients with CF due to severe acute respiratory infection (SARI) in Brazil and we also performed a systematic review including all the studies published from the beginning of the first case of COVID-19 (17 November 2019) to the date of this search (23 May 2022) which included, concomitantly, patients with CF and COVID-19 in the worldwide population. In our Brazilian data, we evaluated the period from December 2019 to March 2022, and we included 33 demographical and clinical patients’ features. We classified the patients into groups: (G1) SARI due to another viral infection than severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (23; 5.4%), (G2) SARI due to an unknown etiological agent (286; 67.1%), and (G3) SARI due to SARS-CoV-2 infection (117; 27.5%). The individuals in G3 tended to be older, especially over 50 years old, and presented a higher prevalence of dyspnea, peripheral capillary oxygen saturation (SpO2) <95%, and cardiopathy. The highest prevalence for intensive care unit (ICU) treatment (52; 44.4%) and invasive mechanical ventilation (29; 24.8%) was for patients in G3. Almost half of the patients in G3 died (51; 43.6%); in contrast, none in G1 died. However, we observed 43 (15.0%) deaths in G2. In addition, 12 (4.2%) and one (0.9%) death not associated with SARI occurred, respectively, in the G2 and G3. The patients who died due to SARS-CoV-2 infection had a higher frequency of SpO2 <95% (46; 90.2%), ICU treatment (34; 66.7%), and invasive mechanical ventilation (27; 52.9%) when compared to those who recovered. The systematic review comprised a total of 31 papers published as observational studies. These studies comprised 661,386 patients in total, including children, adults, and elderly age groups. However, only 19,150 (2.9%) patients were diagnosed with CF and, from these patients, 2523 (0.4%) were diagnosed with both CF and COVID-19. It was observed that the most common outcome was the need for hospitalization (n = 322 patients with CF), and the need for oxygen support (n = 139 patients with CF). One hundred patients with CF needed intensive care units, fifty patients needed non-invasive mechanical ventilation support, and only three patients were described as receiving invasive mechanical ventilation support. Deaths were described in 38 patients with CF. Importantly, lung-transplanted patients with CF represented an increased risk of death in one publication; in accordance, another study described that lung transplantation and moderate to severe lung disease were independent risk factors for severe outcomes after SARS-CoV-2 infection. In contrast with the literature, in conclusion, Brazilian patients in G3 presented a severe phenotype, even though most of the other studies did not observe worse outcomes in patients with CF and COVID-19.

show abstract

“…Moreover, there was no reported data in the Arab Gulf region that reflects the pediatric CF population. However, Alyazidi et al 30 reported COVID-19 infection in three children with CF who required hospitalization during the first year of the COVID-19 wave in three main pediatric hospitals in Oman. Only one patient with moderate-severe CF-related lung disease required respiratory support with non-invasive ventilation.…”

Section: Discussionmentioning

confidence: 99%

The clinical features and impact of SARS-CoV-2/COVID-19 infection in children with Cystic Fibrosis (CF): A Qatari experience

Hamad,

Kammouh,

Alamri

et al. 2023

Qatar Medical Journal

View full text Add to dashboard Cite

Background: SARS-CoV-2 in children with cystic fibrosis (CF) has been reported to cause mild illness without pre-existing severe lung disease. This review described the clinical presentation and course of COVID-19 infection in children with CF in Qatar. Methods: The pediatric CF registry of 51 patients in Qatar was reviewed for COVID-19 cases from February 2020 to February 2022. Demographics, vaccination status, symptoms, and course were reviewed. Data were expressed as median, range, frequencies, and percentages. Results: The study included eight patients with CF below 18 years of age infected with COVID-19. The incidence of COVID-19 in children with CF was 15.7%. The median age was 11 (2-18) years. Half of the cohort were males. Seven patients were pancreatic sufficient (I1234V mutation), and one was pancreatic insufficient (3129del4 mutation). The median baseline FEV1 was 91 (78-107%) predicted. None had received CFTR modulators or undergone a lung transplant. Three patients were vaccinated before their infections. Two of them were asymptomatic. Six patients (75%) had a cough and flu-like symptoms. Three patients had a fever. Two patients were hospitalized due to pulmonary exacerbation; both had mild CF-lung disease. None required respiratory support. Conclusion: We report a favorable outcome of COVID-19 infection in children with CF, similar to published international studies. Our findings are attributable to the community-dominant milder CFTR mutation, precautionary measures, and causative COVID-19 strain. More longitudinal data are needed to study these factors as potential protective mechanisms.

show abstract

CHILDREN WITH CYSTIC FIBROSIS HOSPITALISED WITH COVID‐19: MULTICENTRE EXPERIENCE

Abstract: The effects of telemedicine on asthma control and patients' quality of life in adults: A systematic review and meta-analysis.

Cited by 4 publications

References 5 publications

An Evaluation of the Risk Factors and Respiratory Function Test Change of Children with Cystic Fibrosis Who Contracted COVID-19 Infection

An Evaluation of the Risk Factors and Respiratory Function Test Change of Children with Cystic Fibrosis Who Contracted COVID-19 Infection

Epidemiological Profile of Hospitalized Patients with Cystic Fibrosis in Brazil Due to Severe Acute Respiratory Infection during the COVID-19 Pandemic and a Systematic Review of Worldwide COVID-19 in Those with Cystic Fibrosis

The clinical features and impact of SARS-CoV-2/COVID-19 infection in children with Cystic Fibrosis (CF): A Qatari experience

Contact Info

Product

Resources

About